A new era of cancer immunotherapy: combining revolutionary technologies for enhanced CAR-M therapy

Na Li,Shinan Geng,Zhen-zhen Dong,Ying Jin,Hangjie Ying,Hung-Wing Li and Liyun Shi
DOI: https://doi.org/10.1186/s12943-024-02032-9
IF: 37.3
2024-06-02
Molecular Cancer
Abstract:Significant advancements have been made in the application of chimeric antigen receptor (CAR)-T treatment for blood cancers during the previous ten years. However, its effectiveness in treating solid tumors is still lacking, necessitating the exploration of alternative immunotherapies that can overcome the significant challenges faced by current CAR-T cells. CAR-based immunotherapy against solid tumors shows promise with the emergence of macrophages, which possess robust phagocytic abilities, antigen-presenting functions, and the ability to modify the tumor microenvironment and stimulate adaptive responses. This paper presents a thorough examination of the latest progress in CAR-M therapy, covering both basic scientific studies and clinical trials. This study examines the primary obstacles hindering the realization of the complete potential of CAR-M therapy, as well as the potential strategies that can be employed to overcome these hurdles. With the emergence of revolutionary technologies like in situ genetic modification, synthetic biology techniques, and biomaterial-supported gene transfer, which provide a wider array of resources for manipulating tumor-associated macrophages, we suggest that combining these advanced methods will result in the creation of a new era of CAR-M therapy that demonstrates improved efficacy, safety, and availability.
oncology,biochemistry & molecular biology
What problem does this paper attempt to address?
The problem that this paper attempts to solve is the limitations of the current CAR - T cell therapy in treating solid tumors, such as low efficacy, short duration, and potential off - target effects. In addition, the characteristics of solid tumors, such as dense tissue structure, diverse tumor cells, and the microenvironment that suppresses the immune system, also greatly limit the clinical effect of CAR - T cell therapy. Therefore, researchers are striving to optimize the CAR - T design strategy and explore other immune cells besides T cells, especially macrophages, as a potentially new approach for CAR cell therapy to overcome the application limitations of traditional CAR - T therapy. Specifically, the paper explores the use of chimeric antigen receptor (CAR) technology to engineer macrophages (CAR - M) to improve their therapeutic effect on solid tumors. Macrophages are a potential candidate due to their strong phagocytic ability, antigen - presenting function, and ability to regulate the tumor microenvironment. The paper reviews the latest progress in CAR - M therapy, including basic scientific research and clinical trials, analyzes the main obstacles to realizing the full potential of CAR - M therapy and possible strategies to overcome them. At the same time, the paper also discusses the use of emerging technologies such as synthetic biology technology, gene - editing technology, and gene delivery supported by biomaterials to create a new generation of CAR - M therapy to show higher efficacy, safety, and availability.